Hemostemix Stock Shares Owned By Insiders
HEM Stock | CAD 0.07 0.01 7.14% |
Hemostemix fundamentals help investors to digest information that contributes to Hemostemix's financial success or failures. It also enables traders to predict the movement of Hemostemix Stock. The fundamental analysis module provides a way to measure Hemostemix's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hemostemix stock.
Hemostemix | Shares Owned By Insiders |
Hemostemix Company Shares Owned By Insiders Analysis
Hemostemix's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Hemostemix Shares Owned By Insiders | 9.54 % |
Most of Hemostemix's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hemostemix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Hemostemix Shares Owned By Insiders Driver Correlations
Understanding the fundamental principles of building solid financial models for Hemostemix is extremely important. It helps to project a fair market value of Hemostemix Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since Hemostemix's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Hemostemix's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Hemostemix's interrelated accounts and indicators.
Click cells to compare fundamentals
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Competition |
Based on the latest financial disclosure, 9.54% of Hemostemix are shares owned by insiders. This is 37.15% lower than that of the Biotechnology sector and 32.72% lower than that of the Health Care industry. The shares owned by insiders for all Canada stocks is 5.45% higher than that of the company.
Hemostemix Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hemostemix's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hemostemix could also be used in its relative valuation, which is a method of valuing Hemostemix by comparing valuation metrics of similar companies.Hemostemix is currently under evaluation in shares owned by insiders category among its peers.
Hemostemix Fundamentals
Return On Asset | -3.49 | ||||
Current Valuation | 14.56 M | ||||
Shares Outstanding | 140.64 M | ||||
Shares Owned By Insiders | 9.54 % | ||||
Number Of Shares Shorted | 11.93 K | ||||
Price To Earning | (1.70) X | ||||
Price To Book | 27.76 X | ||||
EBITDA | (2.16 M) | ||||
Net Income | (2.5 M) | ||||
Cash And Equivalents | 49.36 K | ||||
Total Debt | 4.32 M | ||||
Current Ratio | 0.05 X | ||||
Book Value Per Share | (0.09) X | ||||
Cash Flow From Operations | (1.5 M) | ||||
Short Ratio | 0.17 X | ||||
Earnings Per Share | (0.03) X | ||||
Target Price | 0.96 | ||||
Beta | 0.19 | ||||
Market Capitalization | 10.55 M | ||||
Total Asset | 313.76 K | ||||
Retained Earnings | (63.27 M) | ||||
Working Capital | (2.56 M) | ||||
Net Asset | 313.76 K |
About Hemostemix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hemostemix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hemostemix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hemostemix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Hemostemix Stock Analysis
When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.